The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | TACT-D: a randomized study evaluating tailoring of mCRC therapy using ctDNA
Kanwal Pratap Singh Raghav, MBBS, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the TACT-D study (NCT03844620), which evaluates early dynamic changes in circulating tumor DNA (ctDNA) to predict treatment response in metastatic colorectal cancer (mCRC). This randomized study aimed to validate ctDNA changes as indicators of treatment efficacy and adverse events with regorafenib or TAS102. Results showed that baseline ctDNA levels were strongly prognostic of clinical benefit. While the primary endpoints—treatment-related adverse events and objective response rate—showed no significant differences, adjustments for baseline ctDNA revealed that changes in ctDNA were predictive of progression-free and overall survival. These findings suggest the potential of ctDNA monitoring for optimizing mCRC treatment strategies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Honoraria – Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Consulting or Advisory Role – Bayer; Daiichi Sankyo/Astra Zeneca; Eisai; Merck; Seagen
Research Funding – Abbvie (Inst); Bayer (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Eisai (Inst); Guardant Health (Inst); HiberCell (Inst); Innovent Biologics (Inst); Janssen (Inst); Merck Serono (Inst); Roche/Genentech (Inst); UCB (Inst); Xencor (Inst)
